BridgeBio's stock rockets 66% on news of positive results from late-stage trial of ATTR-CM treatment
BridgeBio Pharma Inc.'s stock (BBIO) rocketed 66% in premarket trade Monday, after the company announced positive results in a late-stage trial of a treatment for transthyretin amyloid cardiomyopathy, or ATTR-CM, a buildup of faulty proteins on the heart that can cause heart failure. The Palo Alto, Calif.-based company said the Phase 3 trial of acoramidis achieved a highly statistically significant result on primary endpoint and clinically meaningful results on all measures of mortality, morbidity, function and quality of life. "The consistent and clinically meaningful benefits on survival, hospitalization, and additional measures of illness severity are truly remarkable," said Dr. Daniel Judge, professor of medicine and cardiology at the Medical University of South Carolina, in a statement. The trial achieved an 81% survival rate, versus 74% on placebo. The company intends to submit a New Drug Application to the U.S. Food and Drug Administration before year-end and will follow on with regulatory filings in other markets in 2024. The stock has gained 139% in the year to date, while the S&P 500 has gained 17%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-17-23 0732ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom